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Harnessing the modular architecture of non-ribosomal peptide synthetases for combinatorial biosynthesis is
a longstanding goal in chemical biology. Several recent reports illustrate how computational design and
directed evolution can be used to tailor the specificity of these assembly-line enzymes.The serendipitous discovery of penicillin
80 years ago revolutionized the treatment
of dangerous bacterial infections. It also
showcased a structurally diverse class of
natural products (i.e., non-ribosomal pep-
tides) that exhibit a broad spectrum of
valuable biological and pharmacological
activities. In addition tomany clinically im-
portant antibiotics, these secondary me-
tabolites include potent cytostatic agents,
immunosuppressants, siderophores, and
toxins.
While penicillin is still in use today,
many bacteria are now resistant to the
original drug. Chemists have responded
to this challenge by synthesizing novel
penicillin derivatives that prolong life and
good health, but the need for new and
improved antibiotics (and other agents)
is never-ending. Biological approaches
may soon be able to help; elucidation
of the chemical logic underlying the
biological assembly of non-ribosomal
peptides over the last two decades has
made biosynthesis of non-natural deriva-
tives in microorganisms an enticing
alternative to total synthesis in the labora-
tory. Combinatorial manipulation of these
pathways has significant potential to
expand the molecular diversity of struc-
turally complex natural products, contrib-
uting both to the discovery and optimiza-
tion of pharmacological leads (Cane et al.,
1998).
Non-ribosomal peptides are produced
biologically by gigantic mega-enzymes
called non-ribosomal peptide synthetases
(NRPSs). These enzymes consist of mul-
tiple protein modules, strung together
like beads on a string, that function much
like an assembly line (Sieber andMarahiel,
2005). Each module is responsible for
incorporating one amino acid into the
growing peptide chain, with the length
and composition of the final natural pro-
duct determined by the nature, number,1206 Chemistry & Biology 18, October 28, 20and order of the individual modules. The
substrate specificity of each module is
dictated by an adenylation domain, or A
domain, which recognizes and activates
the appropriate amino acid and tethers it
covalently to the assembly line.
The modular architecture of NRPSs
suggests that it should be possible to
create ‘‘unnatural’’ products simply by re-
placing or modifying the A domains in an
existing NRPS (Figure 1). Protein engi-
neers can take advantage of the large
set of natural A domains that activate hun-
dreds of different amino acids and swap
individual domains or even entiremodules
in NRPSs tomake newpeptides. Because
intermodule communication is still poorly
understood, however, the resulting con-
structs often suffer from poor overall
activity. If an effective screen or selection
is available, laboratory evolution can be
applied to increase the efficiency of these
hybrid systems, as demonstrated for
novel NRPSs that produce andrimid de-
rivatives, potent non-ribosomal peptide/
polyketide antibiotics (Fischbach et al.,
2007).
Reengineering existing A domains rep-
resents an alternative strategy for altering
NRPS specificity that, at least in principle,
enables exploration of substrate prefer-
ences not exhibited by natural A domains.
Using a structurally characterized PheA
domain as a guide, Stachelhaus et al.
(1999) identified a set of ten residues in
the amino acid binding pocket as poten-
tial determinants of substrate specificity.
The sequence variability at these posi-
tions inbiochemically characterizedaden-
ylation domains suggested a set of
general rules, the so-called ‘‘Stachelhaus
code,’’ for predicting substrate prefer-
ences directly from primary sequence.
These predictions have also been used
for rational redesign of A domain selec-
tivity, but changes achievable by single11 ª2011 Elsevier Ltd All rights reservedpoint mutations are typically conservative
(Asp/Asn, Glu/Gln, Phe/Leu) (Sta-
chelhaus et al., 1999; Eppelmann et al.,
2002). Not surprisingly, because of phylo-
genetic bias and relatively small data sets,
sequence-based approaches cannot fully
capture the subtleties underlying amino
acid recognition.
The substrate preferences of many
proteins have been successfully al-
tered by more far-reaching combinatorial
searches of sequence space. Structure-
based computational methods are partic-
ularly attractive in this regard. Algorithms
have been developed that enable rapid
evaluation of thousands of different se-
quences and hundreds of millions of con-
formations. Applying this approach to the
first adenylation domain in gramicidin S,
Chen et al. (2009) achieved a 2000-
fold switch in substrate specificity from
L-phenylalanine to L-leucine. Notable in
this context was the identification of
a novel set of mutations not encountered
in natural A domains, including bolstering
mutations that do not directly contact the
substrate. Although currently limited by
the simplifying assumptions of the com-
putational models, this approach to sub-
strate redesign has enormous potential
and will undoubtedly increase in impor-
tance as the methods become faster
and more accurate.
In the interim, as Villiers and Holl-
felder (2011) report in this issue of Chem-
istry & Biology, experimental evolutionary
searches can also be quite effective.
For example, using a medium-throughput
screen and several rounds of iterative
saturation mutagenesis followed by re-
combination of beneficial mutations, they
successfully repurposed the TycAmodule
of tyrocidine synthetase. Normally, the A
domain of TycA activates L-phenylalanine
five to six orders of magnitude more effi-
ciently than small, hydrophilic substrates
Figure 1. Tailoring the specificity of NRPSs. Novel peptides can bemade by domain splicing,
computational design, or directed evolution of NRPSs. A, adenylation domain; T, thiolation
domain; C, condensation domain.
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course of directed evolution, however,
the weak activity toward the latter could
be significantly enhanced. Relatively few
changes to the specificity determining
residues sterically restricted access to
the active site, leading to a 170-fold
increase in the kcat/Km value for L-Ala
and a concomitant 103-fold decrease in
the kcat/Km value for L-Phe. This 10
5-fold
change in specificity is impressive and
substantially larger than the changes typi-
cally achieved by implementing the
predictions of the ‘‘Stachelhaus code.’’
Nevertheless, the modified TycA variant
is unlike highly evolved A domains in
Nature, since it activates large and
small substrates comparably well. As
such, it is more like the promiscuous in-
termediates postulated to be the evolu-
tionary precursors of modern enzymes. It
will be interesting to seewhether this func-
tional plasticity can be effectively chan-
neled through additional laboratory evolu-
tion to achieve more specialized amino
acid recognition.Recent work by Evans et al. (2011) indi-
cates that this basic strategy is not re-
stricted to isolated A domains. They gen-
erated libraries of the AdmKmodule of the
andrimid biosynthetic gene cluster, tar-
geting three of the specificity determin-
ing active site residues of the A domain
for saturation mutagenesis. These were
expressed in the native host, Pantoea
agglomerans, and the >14,000-member
library was screened directly for the
production of andrimid-like metabolites
using a highly sensitive mass spectro-
metric technique. Several clones were
identified that produced four bioactive an-
drimid derivatives, three of which were
new. Interestingly, the AdmK variants all
exhibited broadened substrate specificity
relative to the wild-type NRPS; two even
had promiscuous activity resembling
that of the TycA variant just discussed,
inserting mixtures of L-alanine and
L-phenylalanine in place of the normal
substrate L-valine. Although only a single
round of mutagenesis and screening
was performed, this integrated in vivoChemistry & Biology 18, October 28, 2011 ªapproach will facilitate further evolution
and should be readily extendable to
larger libraries and other biosynthetic
enzymes.
The proof-of-concept experiments de-
scribed in this short perspective highlight
important progress toward the redesign
of NRPS specificity. While reliable, on-
demand biosynthesis of complex natural
product analogs remains a distant goal, it
can be expected that in silico design and
experimental evolution, either individu-
ally or, more powerfully, in combination,
will significantly expand the toolkit for
constructing non-ribosomal peptides.
Indeed, advances in this area will likely
fuel design and manufacture of novel
therapeutic agents of many kinds in the
years to come.REFERENCES
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